Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Titel:
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Auteur:
Venter, Willem D F Sokhela, Simiso Simmons, Bryony Moorhouse, Michelle Fairlie, Lee Mashabane, Nkuli Serenata, Celicia Akpomiemie, Godspower Masenya, Masebole Qavi, Ambar Chandiwana, Nomathemba McCann, Kaitlyn Norris, Shane Chersich, Matthew Maartens, Gary Lalla-Edward, Samanta Vos, Alinda Clayden, Polly Abrams, Elaine Arulappan, Natasha Hill, Andrew